SCHEMBL4753189

SCHEMBL4753189

CCc1cc2c([nH]1)CCCC2

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.42
HPGD P15428 4/20 0.42
KDM4E B2RXH2 4/20 0.42
HSD17B10 Q99714 3/20 0.42
MAPT P10636 6/20 0.41
NPSR1 Q6W5P4 2/20 0.41
APOBEC3G Q9HC16 1/20 0.41
ALOX15 P16050 2/20 0.40
ALOX12 P18054 2/20 0.40
HRH4 Q9H3N8 1/20 0.39
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
LMNA P02545 3/20 0.34
TDP1 Q9NUW8 2/20 0.34
TP53 P04637 2/20 0.34
TSHR P16473 2/20 0.34
MAPK1 P28482 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
SRC P12931 3/20 0.33
HTT P42858 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13318356 0.79 ALDH1A1 (0.42) ALDH1A1HPGDKDM4EHSD17B10MAPT
SCHEMBL8153296 0.76 KDM4E (0.33) ALDH1A1HPGDKDM4EHSD17B10MAPT
SCHEMBL20884972 0.75 PKN2 (0.45) KMT2AF12
SCHEMBL22016185 0.75 ALDH1A1 (0.50) ALDH1A1HPGDKDM4EHSD17B10MAPT
SCHEMBL9455140 0.72 GABRA1 (0.51) ALDH1A1HPGDKDM4EHSD17B10MAPT
SCHEMBL12844664 0.71
SCHEMBL7959781 0.71 ALDH1A1 (0.46) ALDH1A1HPGDKDM4EHSD17B10MAPT
SCHEMBL6809204 0.71 HSD17B10 (0.50) ALDH1A1HPGDKDM4EHSD17B10MAPT
SCHEMBL9454837 0.71 GABRA1 (0.50) ALDH1A1HPGDKDM4EHSD17B10MAPT
SCHEMBL21040048 0.70 ALDH1A1 (0.46) ALDH1A1HPGDKDM4EHSD17B10MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2013029548-A1 QUINOLONE COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-07 WO disclosed
US-20110301145-A1 PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF Gilead Connecticut INc. (US) 2011-12-08 US disclosed
WO-2008147246-A1 CATALYST FOR DEHYDROGENATION OF 4,5,6,7 TETRAHYDROINDOLE INTO INDOLE AND METHOD FOR PREPARING THEREOF A.E. FAVORSKY IRKUTSK INSTITUTE OF CHEMISTRY SIBERIAN BRANCH RUSSIAN ACADEMY OF SCIENCES (IRIH SB RAS) (RU) 2008-12-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110301145-A1 PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF BTK, SYK, LCK ALDH1A1 3488/4885HPGD 858/4885KDM4E 1767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.